Regulation of the retinoblastoma-E2F pathway by the ubiquitin-proteasome system

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1849, Issue 10, 2015, Pages 1289-1297

  Sengupta, Satyaki ^a   Henry, R William ^a  

^a Michigan State University   (United States)

Author keywords

E2F; P107; P130; Proteasome; RB; Retinoblastoma; Transcription regulation; Ubiquitin

Indexed keywords

PROTEASOME; TRANSCRIPTION FACTOR E2F; UBIQUITIN; BCAR1 PROTEIN, HUMAN; CRK ASSOCIATED SUBSTRATE PROTEIN; CYCLIN DEPENDENT KINASE; DNA BINDING PROTEIN; PROTEIN P107; RETINOBLASTOMA PROTEIN;

CELL CYCLE; DNA DAMAGE; GENE CONTROL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TARGETING; REGULATORY MECHANISM; RETINOBLASTOMA; REVIEW; TRANSCRIPTION REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM;

CRK-ASSOCIATED SUBSTRATE PROTEIN; CYCLIN-DEPENDENT KINASES; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA-LIKE PROTEIN P107; TRANSCRIPTION, GENETIC; UBIQUITIN;

EID: 84941266305     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2015.08.008     Document Type: Review

References (132)

1. Dick F.A., Rubin S.M. Molecular mechanisms underlying RB protein function. Nat. Rev. Mol. Cell Biol. 2013, 14:297-306.
2. Stevaux O., Dimova D., Frolov M.V., Taylor-Harding B., Morris E., Dyson N. Distinct mechanisms of E2F regulation by Drosophila RBF1 and RBF2. EMBO J. 2002, 21:4927-4937.
3. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998, 12:2245-2262.
4. Lammens T., Li J., Leone G., De Veylder L. Atypical E2Fs: new players in the E2F transcription factor family. Trends Cell Biol. 2009, 19:111-118.
5. Trimarchi J.M., Lees J.A. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 2002, 3:11-20.
6. Takahashi Y., Rayman J.B., Dynlacht B.D. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev. 2000, 14:804-816.
7. Flemington E.K., Speck S.H., Kaelin W.G. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:6914-6918.
8. Helin K., Harlow E., Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol. Cell. Biol. 1993, 13:6501-6508.
9. Hiebert S.W., Chellappan S.P., Horowitz J.M., Nevins J.R. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev. 1992, 6:177-185.
10. Lees J.A., Saito M., Vidal M., Valentine M., Look T., Harlow E., Dyson N., Helin K. The retinoblastoma protein binds to a family of E2F transcription factors. Mol. Cell. Biol. 1993, 13:7813-7825.
11. Qin X.Q., Chittenden T., Livingston D.M., Kaelin W.G. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 1992, 6:953-964.
12. Cecchini M.J., Dick F.A. The biochemical basis of CDK phosphorylation-independent regulation of E2F1 by the retinoblastoma protein. Biochem. J. 2011, 434:297-308.
13. Dick F.A., Dyson N. pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol. Cell 2003, 12:639-649.
14. Hiebert S.W. Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-mediated growth suppression. Mol. Cell. Biol. 1993, 13:3384-3391.
15. Julian L.M., Palander O., Seifried L.A., Foster J.E., Dick F.A. Characterization of an E2F1-specific binding domain in pRB and its implications for apoptotic regulation. Oncogene 2008, 27:1572-1579.
16. Rubin S.M., Gall A.L., Zheng N., Pavletich N.P. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell 2005, 123:1093-1106.
17. Buchkovich K., Duffy L.A., Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 1989, 58:1097-1105.
18. Chen P.L., Scully P., Shew J.Y., Wang J.Y., Lee W.H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989, 58:1193-1198.
19. Hinds P.W., Mittnacht S., Dulic V., Arnold A., Reed S.I., Weinberg R.A. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992, 70:993-1006.
20. Lundberg A.S., Weinberg R.A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct Cyclin-Cdk complexes. Mol. Cell. Biol. 1998, 18:753-761.
21. Rubin S.M. Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem. Sci. 2013, 38:12-19.
22. Narasimha A.M., Kaulich M., Shapiro G.S., Choi Y.J., Sicinski P., Dowdy S.F. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. Elife 2014, e02872.
23. Craney A., Rape M. Dynamic regulation of ubiquitin-dependent cell cycle control. Curr. Opin. Cell Biol. 2013, 25:704-710.
24. Teixeira L.K., Reed S.I. Ubiquitin ligases and cell cycle control. Annu. Rev. Biochem. 2013, 82:387-414.
25. Bhattacharya S., Garriga J., Calbo J., Yong T., Haines D.S., Grana X. SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. Oncogene 2003, 22:2443-2451.
26. Tedesco D., Lukas J., Reed S.I. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF (Skp2). Genes Dev. 2002, 16:2946-2957.
27. Beijersbergen R.L., Carlee L., Kerkhoven R.M., Bernards R. Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes. Genes Dev. 1995, 9:1340-1353.
28. Wei W., Ayad N.G., Wan Y., Zhang G.J., Kirschner M.W., Kaelin W.G. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 2004, 428:194-198.
29. Wirbelauer C., Sutterluty H., Blondel M., Gstaiger M., Peter M., Reymond F., Krek W. The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. EMBO J. 2000, 19:5362-5375.
30. Zhang H., Kobayashi R., Galaktionov K., Beach D. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995, 82:915-925.
31. Furukawa Y., Iwase S., Kikuchi J., Nakamura M., Yamada H., Matsuda M. Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes. Oncogene 1999, 18:2003-2014.
32. De Luca A., MacLachlan T.K., Bagella L., Dean C., Howard C.M., Claudio P.P., Baldi A., Khalili K., Giordano A. A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity. J. Biol. Chem. 1997, 272:20971-20974.
33. Carrano A.C., Eytan E., Hershko A., Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1999, 1:193-199.
34. Rivadeneira D.B., Mayhew C.N., Thangavel C., Sotillo E., Reed C.A., Grana X., Knudsen E.S. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology 2010, 138:1920-1930.
35. Sengupta S., Lingnurkar R., Carey T.S., Pomaville M., Kar P., Feig M., Wilson C.A., Knott J.G., Arnosti D.N., Henry R.W. The evolutionarily conserved C-terminal domains in the mammalian retinoblastoma tumor suppressor family serve as dual regulators of protein stability and transcriptional potency. J. Biol. Chem. 2015, 290:14462-14475.
36. Acharya P., Raj N., Buckley M.S., Zhang L., Duperon S., Williams G., Henry R.W., Arnosti D.N. Paradoxical instability-activity relationship defines a novel regulatory pathway for retinoblastoma proteins. Mol. Biol. Cell 2010, 21:3890-3901.
37. Smith E.J., Leone G., Nevins J.R. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell Growth Differ. 1998, 9:297-303.
38. Markiewicz E., Dechat T., Foisner R., Quinlan R.A., Hutchison C.J. Lamin A/C binding protein LAP2alpha is required for nuclear anchorage of retinoblastoma protein. Mol. Biol. Cell 2002, 13:4401-4413.
39. Johnson B.R., Nitta R.T., Frock R.L., Mounkes L., Barbie D.A., Stewart C.L., Harlow E., Kennedy B.K. A-type lamins regulate retinoblastoma protein function by promoting subnuclear localization and preventing proteasomal degradation. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9677-9682.
40. Nitta R.T., Smith C.L., Kennedy B.K. Evidence that proteasome-dependent degradation of the retinoblastoma protein in cells lacking A-type lamins occurs independently of gankyrin and MDM2. PLoS One 2007, 2.
41. Nitta R.T., Jameson S.A., Kudlow B.A., Conlan L.A., Kennedy B.K. Stabilization of the retinoblastoma protein by A-type nuclear lamins is required for INK4A-mediated cell cycle arrest. Mol. Cell. Biol. 2006, 26:5360-5372.
42. Higashitsuji H., Itoh K., Nagao T., Dawson S., Nonoguchi K., Kido T., Mayer R.J., Arii S., Fujita J. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med. 2000, 6:96-99.
43. Higashitsuji H., Liu Y., Mayer R.J., Fujita J. The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation. Cell Cycle 2005, 4:1335-1337.
44. Marji J., O'Donoghue S.I., McClintock D., Satagopam V.P., Schneider R., Ratner D., Worman H.J., Gordon L.B., Djabali K. Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition. PLoS One 2010, 5.
45. Sdek P., Ying H., Chang D.L., Qiu W., Zheng H., Touitou R., Allday M.J., Xiao Z.X. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol. Cell 2005, 20:699-708.
46. Sdek P., Ying H., Zheng H., Margulis A., Tang X., Tian K., Xiao Z.X. The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J. Biol. Chem. 2004, 279:53317-53322.
47. Uchida C., Miwa S., Kitagawa K., Hattori T., Isobe T., Otani S., Oda T., Sugimura H., Kamijo T., Ookawa K., Yasuda H., Kitagawa M. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 2005, 24:160-169.
48. Xiao Z.X., Chen J., Levine A.J., Modjtahedi N., Xing J., Sellers W.R., Livingston D.M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995, 375:694-698.
49. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., Antipin Y., Reva B., Goldberg A.P., Sander C., Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-404.
50. Dubs-Poterszman M.C., Tocque B., Wasylyk B. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 1995, 11:2445-2449.
51. Uchida C., Miwa S., Isobe T., Kitagawa K., Hattori T., Oda T., Yasuda H., Kitagawa M. Effects of MdmX on Mdm2-mediated downregulation of pRB. FEBS Lett. 2006, 580:1753-1758.
52. Zhang H., Hu L., Qiu W., Deng T., Zhang Y., Bergholz J., Xiao Z.X. MDMX exerts its oncogenic activity via suppression of retinoblastoma protein. Oncogene 2015, 10.1038/onc.2015.11.
53. Chellappan S., Kraus V.B., Kroger B., Munger K., Howley P.M., Phelps W.C., Nevins J.R. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4549-4553.
54. Dyson N., Howley P.M., Munger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243:934-937.
55. Munger K., Werness B.A., Dyson N., Phelps W.C., Harlow E., Howley P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 1989, 8:4099-4105.
56. Banks L., Edmonds C., Vousden K.H. Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene 1990, 5:1383-1389.
57. Brokaw J.L., Yee C.L., Munger K. A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein. Virology 1994, 205:603-607.
58. Edmonds C., Vousden K.H. A point mutational analysis of human papillomavirus type 16 E7 protein. J. Virol. 1989, 63:2650-2656.
59. Jewers R.J., Hildebrandt P., Ludlow J.W., Kell B., McCance D.J. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J. Virol. 1992, 66:1329-1335.
60. Boyer S.N., Wazer D.E., Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996, 56:4620-4624.
61. Gonzalez S.L., Stremlau M., He X., Basile J.R., Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J. Virol. 2001, 75:7583-7591.
62. Lee J.O., Russo A.A., Pavletich N.P. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 1998, 391:859-865.
63. Huh K., Zhou X., Hayakawa H., Cho J.Y., Libermann T.A., Jin J., Harper J.W., Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 2007, 81:9737-9747.
64. White E.A., Sowa M.E., Tan M.J., Jeudy S., Hayes S.D., Santha S., Munger K., Harper J.W., Howley P.M. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E260-267.
65. Litovchick L., Sadasivam S., Florens L., Zhu X., Swanson S.K., Velmurugan S., Chen R., Washburn M.P., Liu X.S., DeCaprio J.A. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol. Cell 2007, 26:539-551.
66. Sadasivam S., DeCaprio J.A. The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat. Rev. Cancer 2013, 13:585-595.
67. Sadasivam S., Duan S., DeCaprio J.A. The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev. 2012, 26:474-489.
68. Korenjak M., Taylor-Harding B., Binne U.K., Satterlee J.S., Stevaux O., Aasland R., White-Cooper H., Dyson N., Brehm A. Native E2F/RBF complexes contain Myb-interacting proteins and repress transcription of developmentally controlled E2F target genes. Cell 2004, 119:181-193.
69. Lewis P.W., Beall E.L., Fleischer T.C., Georlette D., Link A.J., Botchan M.R. Identification of a Drosophila Myb-E2F2/RBF transcriptional repressor complex. Genes Dev. 2004, 18:2929-2940.
70. Nor Rashid N., Yusof R., Watson R.J. Disruption of repressive p130-DREAM complexes by human papillomavirus 16 E6/E7 oncoproteins is required for cell-cycle progression in cervical cancer cells. J. Gen. Virol. 2011, 92:2620-2627.
71. Pang C.L., Toh S.Y., He P., Teissier S., Ben Khalifa Y., Xue Y., Thierry F. A functional interaction of E7 with B-Myb-MuvB complex promotes acute cooperative transcriptional activation of both S- and M-phase genes. (129 c). Oncogene 2014, 33:4039-4049.
72. Knight J.S., Sharma N., Robertson E.S. Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18562-18566.
73. Munakata T., Liang Y., Kim S., McGivern D.R., Huibregtse J., Nomoto A., Lemon S.M. Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog. 2007, 3:1335-1347.
74. Munakata T., Nakamura M., Liang Y., Li K., Lemon S.M. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18159-18164.
75. Hsiao K.M., McMahon S.L., Farnham P.J. Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev. 1994, 8:1526-1537.
76. Neuman E., Flemington E.K., Sellers W.R., Kaelin W.G. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol. Cell. Biol. 1994, 14:6607-6615.
77. Dynlacht B.D., Flores O., Lees J.A., Harlow E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev. 1994, 8:1772-1786.
78. Krek W., Ewen M.E., Shirodkar S., Arany Z., Kaelin W.G., Livingston D.M. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 1994, 78:161-172.
79. Biswas A.K., Johnson D.G. Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res. 2012, 72:13-17.
80. Asano M., Nevins J.R., Wharton R.P. Ectopic E2F expression induces S phase and apoptosis in Drosophila imaginal discs. Genes Dev. 1996, 10:1422-1432.
81. Marti A., Wirbelauer C., Scheffner M., Krek W. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat. Cell Biol. 1999, 1:14-19.
82. Peart M.J., Poyurovsky M.V., Kass E.M., Urist M., Verschuren E.W., Summers M.K., Jackson P.K., Prives C. APC/C(Cdc20) targets E2F1 for degradation in prometaphase. Cell Cycle 2010, 9:3956-3964.
83. Campanero M.R., Flemington E.K. Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2221-2226.
84. Hateboer G., Kerkhoven R.M., Shvarts A., Bernards R., Beijersbergen R.L. Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev. 1996, 10:2960-2970.
85. Hofmann F., Martelli F., Livingston D.M., Wang Z. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev. 1996, 10:2949-2959.
86. Martelli F., Livingston D.M. Regulation of endogenous E2F1 stability by the retinoblastoma family proteins. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2858-2863.
87. Shibutani S., Swanhart L.M., Duronio R.J. Rbf1-independent termination of E2f1-target gene expression during early Drosophila embryogenesis. Development 2007, 134:467-478.
88. Zielke N., Kim K.J., Tran V., Shibutani S.T., Bravo M.J., Nagarajan S., van Straaten M., Woods B., von Dassow G., Rottig C., Lehner C.F., Grewal S.S., Duronio R.J., Edgar B.A. Control of Drosophila endocycles by E2F and CRL4(CDT2). Nature 2011, 480:123-127.
89. Shibutani S.T., de la Cruz A.F., Tran V., Turbyfill W.J., Reis T., Edgar B.A., Duronio R.J. Intrinsic negative cell cycle regulation provided by PIP box- and Cul4Cdt2-mediated destruction of E2f1 during S phase. Dev. Cell 2008, 15:890-900.
90. Ianari A., Gallo R., Palma M., Alesse E., Gulino A. Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. J. Biol. Chem. 2004, 279:30830-30835.
91. Lin W.C., Lin F.T., Nevins J.R. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 2001, 15:1833-1844.
92. Davidson J.M., Duronio R.J. S phase-coupled E2f1 destruction ensures homeostasis in proliferating tissues. PLoS Genet. 2012, 8.
93. Zhang L., Wang C. F-box protein Skp2: a novel transcriptional target of E2F. Oncogene 2006, 25:2615-2627.
94. Chicas A., Wang X., Zhang C., McCurrach M., Zhao Z., Mert O., Dickins R.A., Narita M., Zhang M., Lowe S.W. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 2010, 17:376-387.
95. Yung Y., Walker J.L., Roberts J.M., Assoian R.K. A Skp2 autoinduction loop and restriction point control. J. Cell Biol. 2007, 178:741-747.
96. Rodier G., Makris C., Coulombe P., Scime A., Nakayama K., Nakayama K.I., Meloche S. p107 inhibits G1 to S phase progression by down-regulating expression of the F-box protein Skp2. J. Cell Biol. 2005, 168:55-66.
97. Ji P., Jiang H., Rekhtman K., Bloom J., Ichetovkin M., Pagano M., Zhu L. An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol. Cell 2004, 16:47-58.
98. Assoian R.K., Yung Y. A reciprocal relationship between Rb and Skp2: implications for restriction point control, signal transduction to the cell cycle and cancer. Cell Cycle 2008, 7:24-27.
99. Binne U.K., Classon M.K., Dick F.A., Wei W., Rape M., Kaelin W.G., Naar A.M., Dyson N.J. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat. Cell Biol. 2007, 9:225-232.
100. Wang H., Bauzon F., Ji P., Xu X., Sun D., Locker J., Sellers R.S., Nakayama K., Nakayama K.I., Cobrinik D., Zhu L. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice. Nat. Genet. 2010, 42:83-88.
101. Bauzon F., Zhu L. Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality. Cell Cycle 2010, 9:2118-2123.
102. Lu Z., Bauzon F., Fu H., Cui J., Zhao H., Nakayama K., Nakayama K.I., Zhu L. Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity. Nat. Commun. 2014, 5:3463.
103. Zhao H., Bauzon F., Fu H., Lu Z., Cui J., Nakayama K., Nakayama K.I., Locker J., Zhu L. Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors. Cancer Cell 2013, 24:645-659.
104. Xu X.L., Singh H.P., Wang L., Qi D.L., Poulos B.K., Abramson D.H., Jhanwar S.C., Cobrinik D. Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature 2014, 514:385-388.
105. Sangwan M., McCurdy S.R., Livne-Bar I., Ahmad M., Wrana J.L., Chen D., Bremner R. Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation. Oncogene 2012, 31:5019-5028.
106. McCann T.S., Tansey W.P. Functions of the proteasome on chromatin. Biomolecules 2014, 4:1026-1044.
107. Salghetti S.E., Muratani M., Wijnen H., Futcher B., Tansey W.P. Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3118-3123.
108. Zhou W., Srinivasan S., Nawaz Z., Slingerland J.M. ERalpha, SKP2 and E2F-1 form a feed forward loop driving late ERalpha targets and G1 cell cycle progression. Oncogene 2014, 33:2341-2353.
109. Geng F., Tansey W.P. Similar temporal and spatial recruitment of native 19S and 20S proteasome subunits to transcriptionally active chromatin. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:6060-6065.
110. Salghetti S.E., Caudy A.A., Chenoweth J.G., Tansey W.P. Regulation of transcriptional activation domain function by ubiquitin. Science 2001, 293:1651-1653.
111. Kurosu T., Peterlin B.M. VP16 and ubiquitin; binding of P-TEFb via its activation domain and ubiquitin facilitates elongation of transcription of target genes. Curr. Biol. 2004, 14:1112-1116.
112. Wang W., Xue Y., Zhou S., Kuo A., Cairns B.R., Crabtree G.R. Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev. 1996, 10:2117-2130.
113. Li X.S., Trojer P., Matsumura T., Treisman J.E., Tanese N. Mammalian SWI/SNF-a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B. Mol. Cell. Biol. 2010, 30:1673-1688.
114. Dunaief J.L., Strober B.E., Guha S., Khavari P.A., Alin K., Luban J., Begemann M., Crabtree G.R., Goff S.P. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 1994, 79:119-130.
115. Strober B.E., Dunaief J.L., Guha S.P., Goff Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Mol. Cell. Biol. 1996, 16:1576-1583.
116. Strobeck M.W., Knudsen K.E., Fribourg A.F., DeCristofaro M.F., Weissman B.E., Imbalzano A.N., Knudsen E.S. BRG-1 is required for RB-mediated cell cycle arrest. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:7748-7753.
117. Hirsch H.A., Gu L., Henry R.W. The retinoblastoma tumor suppressor protein targets distinct general transcription factors to regulate RNA polymerase III gene expression. Mol. Cell. Biol. 2000, 20:9182-9191.
118. Hirsch H.A., Jawdekar G.W., Lee K.A., Gu L., Henry R.W. Distinct mechanisms for repression of RNA polymerase III transcription by the retinoblastoma tumor suppressor protein. Mol. Cell. Biol. 2004, 24:5989-5999.
119. Raj N., Zhang L., Wei Y., Arnosti D.N., Henry R.W. Ubiquitination of retinoblastoma family protein 1 potentiates gene-specific repression function. J. Biol. Chem. 2012, 287:41835-41843.
120. Zhang L., Wei Y., Pushel I., Heinze K., Elenbaas J., Henry R.W., Arnosti D.N. Integrated stability and activity control of the Drosophila Rbf1 retinoblastoma protein. J. Biol. Chem. 2014, 289:24863-24873.
121. Raj N., Zhang L., Wei Y., Arnosti D.N., Henry R.W. Rbf1 degron dysfunction enhances cellular DNA replication. Cell Cycle 2012, 11:3731-3738.
122. Acharya P., Negre N., Johnston J., Wei Y., White K.P., Henry R.W., Arnosti D.N. Evidence for autoregulation and cell signaling pathway regulation from genome-wide binding of the Drosophila retinoblastoma protein. G3 (Bethesda) 2012, 2:1459-1472.
123. Elenbaas J.S., Mouawad R., Henry R.W., Arnosti D.N., Payankaulam S. Role of Drosophila retinoblastoma protein instability element in cell growth and proliferation. Cell Cycle 2015, 14:589-597.
124. Wei Y., Mondal S.S., Mouawad R., Wilczynski B., Henry R.W., Arnosti D.N. Genome-wide analysis of Drosophila RBf2 protein highlights the diversity of RB family targets and possible role in regulation of ribosome biosynthesis. G3 (Bethesda) 2015, 5:1503-1515.
125. Ullah Z., Buckley M.S., Arnosti D.N., Henry R.W. Retinoblastoma protein regulation by the COP9 signalosome. Mol. Biol. Cell 2007, 18:1179-1186.
126. Wei N., Serino G., Deng X.W. The COP9 signalosome: more than a protease. Trends Biochem. Sci. 2008, 33:592-600.
127. Singer R., Atar S., Atias O., Oron E., Segal D., Hirsch J.A., Tuller T., Orian A., Chamovitz D.A. Drosophila COP9 signalosome subunit 7 interacts with multiple genomic loci to regulate development. Nucleic Acids Res. 2014, 42:9761-9770.
128. Menon S., Chi H., Zhang H., Deng X.W., Flavell R.A., Wei N. COP9 signalosome subunit 8 is essential for peripheral T cell homeostasis and antigen receptor-induced entry into the cell cycle from quiescence. Nat. Immunol. 2007, 8:1236-1245.
129. Adler A.S., Lin M., Horlings H., Nuyten D.S., van de Vijver M.J., Chang H.Y. Genetic regulators of large-scale transcriptional signatures in cancer. Nat. Genet. 2006, 38:421-430.
130. Hallstrom T.C., Mori S., Nevins J.R. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008, 13:11-22.
131. Hallstrom T.C., Nevins J.R. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10848-10853.
132. Hallstrom T.C., Nevins J.R. Jab1 is a specificity factor for E2F1-induced apoptosis. Genes Dev. 2006, 20:613-623.